Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 6/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | PDE7B | Q9NP56 | 3/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 6/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.43 |
| ▸ | GSTM2 | P28161 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | KDM4A | O75164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30338244 | 0.85 | PDE7A (0.65) | PDE7ASMN1; SMN2PDE7BSLC6A2SLC6A4 | |
| SCHEMBL1713219 | 0.85 | PDE7A (0.65) | PDE7ASMN1; SMN2PDE7BSLC6A2SLC6A4 | |
| SCHEMBL875772 | 0.81 | PDE7A (0.78) | PDE7ASMN1; SMN2PDE7BSLC6A2SLC6A4 | |
| SCHEMBL31272173 | 0.81 | PDE7A (0.78) | PDE7ASMN1; SMN2PDE7BSLC6A2SLC6A4 | |
| SCHEMBL4845838 | 0.80 | PDE7A (0.55) | PDE7ASMN1; SMN2PDE7BMAPTALDH1A1 | |
| SCHEMBL641092 | 0.79 | PDE7A (0.63) | PDE7ASMN1; SMN2PDE7BSLC6A2SLC6A4 | |
| SCHEMBL7665295 | 0.79 | PDE7A (0.67) | PDE7ASMN1; SMN2PDE7BMEN1KMT2A | |
| SCHEMBL11760310 | 0.79 | PDE7A (0.56) | PDE7ASMN1; SMN2PDE7BSLC6A2SLC6A4 | |
| SCHEMBL10923003 | 0.79 | PDE7A (0.65) | PDE7ASMN1; SMN2PDE7BSLC6A2SLC6A4 | |
| SCHEMBL9186731 | 0.79 | PDE7A (0.56) | PDE7ASMN1; SMN2PDE7BSLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111875516-A | Preparation method of oseltamivir carboxylate and atomizing agent thereof | 上海爱科百发生物医药技术有限公司 | 2020-11-03 | — | — | CN | disclosed |
| CN-107663158-B | Preparation method of oseltamivir carboxylate and atomizing agent thereof | 上海爱科百发生物医药技术有限公司 | 2020-10-02 | — | — | CN | disclosed |
| US-20100240584-A1 | Nematode-extracted serine protease inhibitors and anticoagulant proteins | DENDREON PHARMACEUTICALS, INC. | 2010-09-23 | — | — | US | disclosed |
| EP-0788546-B9 | NEMATODE-EXTRACTED SERINE PROTEASE INHIBITORS AND ANTICOAGULANT PROTEINS | DENDREON CORP (US) | 2007-06-13 | — | — | EP | disclosed |
| EP-1772516-A1 | Pharmaceutical compositions for the treatment of thrombosis | DENDREON CORPORATION (US) | 2007-04-11 | — | — | EP | disclosed |
| EP-0788546-B1 | NEMATODE-EXTRACTED SERINE PROTEASE INHIBITORS AND ANTICOAGULANT PROTEINS | DENDREON CORP (US) | 2006-11-29 | — | — | EP | disclosed |
| US-20060246547-A1 | Nematode-extracted serine protease inhibitors and anticoagulant proteins | DENDREON CORPORATION, A DELAWARE CORPORATION | 2006-11-02 | — | — | US | disclosed |
| US-20050191724-A1 | Nematode-extracted serine protease inhibitors and anticoagulant proteins | CORVAS INTERNATIONAL, INC., A DELAWARE CORPORATION | 2005-09-01 | — | — | US | disclosed |
| US-6872808-B1 | Nematode-extracted serine protease inhibitors and anticoagulant proteins | CORVAS INTERNATIONAL, INC. (US) | 2005-03-29 | — | — | US | disclosed |
| US-6534629-B1 | Isolated protein inhibiting blood coagulation factor X; use in drugs | CORVAS INTERNATIONAL, INC. | 2003-03-18 | — | — | US | disclosed |
| US-5955294-A | SCREENING FOR FACTOR VII/TISSUE FACTOR INHIBITORS BY DETERMINING CLOTTING TIME IN EX VIVO PROTHROMBIN TIME AND ACTIVATED PARTIAL THROBOPLASTIN TIME ASSAY, CALCULATION OF PROLONGATION OF CLOTTING AND RATIOS BETWEEN ASSAYS | CORVAS INTERNATIONAL, INC. (US) | 1999-09-21 | — | — | US | disclosed |
| US-5945275-A | A RECOMBINANT CDNA MOLECULE ISOLATED FROM A NEMATODE SPECIES;FOR PREVENTING BLOOD CLOTTING IN COLLECTION TUBES, TREATMENT OF THROMBOSIS AND ARTHEROSCOLERSIS | CORVAS INTERNATIONAL, INC. (US) | 1999-08-31 | — | — | US | disclosed |
| US-5872098-A | Nematode-extracted anticoagulant protein | CORVAS INTERNATIONAL, INC. (US) | 1999-02-16 | — | — | US | disclosed |
| US-5866542-A | DNA EXPRESSION SYSTEM | CORVAS INTERNATIONAL, INC. (US) | 1999-02-02 | — | — | US | disclosed |
| US-5866543-A | DNA EXPRESSION SYSTEM | CORVAS INTERNATIONAL, INC. (US) | 1999-02-02 | — | — | US | disclosed |
| US-5864009-A | INCLUDING AT LEAST ONE NEMATODE-EXTRACTED ANTICOAGULANT PROTEIN DOMAIN (?NAP DOMAIN?), WHEREIN SAID NAP DOMAIN HAS AN AMINO ACID SEQUENCE HAVING A MOLECULAR WEIGHT OF ABOUT 8.7 TO 8.8 KILODALTONS, AND CONTAINS TEN CYSTEINE AMINO ACID RESIDUES | CORVAS INTERNATIONAL, INC. (US) | 1999-01-26 | — | — | US | disclosed |
| US-5863894-A | SERINE PROTEASE INHIBITOR PROTEIN CONTAINING ONE OR MORE NEMATODE-EXTRACTED ANTICOAGULANT PROTEIN (NAP) DOMAIN | CORVAS INTERNATIONAL, INC. (US) | 1999-01-26 | — | — | US | disclosed |
| EP-0788546-A1 | NEMATODE-EXTRACTED SERINE PROTEASE INHIBITORS AND ANTICOAGULANT PROTEINS | CORVAS INTERNATIONAL, INC. (US) | 1997-08-13 | — | — | EP | disclosed |
| WO-1996012021-A9 | NEMATODE-EXTRACTED SERINE PROTEASE INHIBITORS AND ANTICOAGULANT PROTEINS | — | 1996-06-27 | — | — | WO | disclosed |
| WO-1996012021-A2 | NEMATODE-EXTRACTED SERINE PROTEASE INHIBITORS AND ANTICOAGULANT PROTEINS | CORVAS INTERNATIONAL, INC. (US) | 1996-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240584-A1 | Nematode-extracted serine protease inhibitors and anticoagulant proteins | HABP2, HPN, SERPINC1 | PDE7A 2007/4885SMN1; SMN2 2096/4885PDE7B 2094/4885 |
| US-20060246547-A1 | Nematode-extracted serine protease inhibitors and anticoagulant proteins | HABP2, HPN, SERPINC1 | PDE7A 1923/4885SMN1; SMN2 2086/4885PDE7B 1997/4885 |
| US-20050191724-A1 | Nematode-extracted serine protease inhibitors and anticoagulant proteins | HABP2, HPN, SERPINC1 | PDE7A 1923/4885SMN1; SMN2 2086/4885PDE7B 1997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.